Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Sanofi Ventures
AI-generated illustration
Organisation

Sanofi Ventures

Corporate venture Arm of the French drugmaker Sanofi; an existing backer of T-Therapeutics.

Last refreshed: 14 November 2026

Key Question

Why do big drugmakers keep buying into Cambridge T-cell receptor startups?

Timeline for Sanofi Ventures

#17 5 Nov

T-Therapeutics raises $133m in Series B

UK Startups and Innovation
View full timeline →

Background

Sanofi Ventures, the corporate venture Arm of the French drugmaker Sanofi, is an existing investor in T-Therapeutics, the Cambridge spinout that raised a $133m Series B on 5 November 2026. Its register mixes Advent Life Sciences, the British Business Bank, Eli Lilly, Johnson & Johnson's JJDC, Sanofi Ventures and Tencent, because no single investor class will fund drug development to proof of concept.

Sanofi itself has bought British biotech before: it acquired Kymab, a Cambridge antibody company, in 2021.

Common Questions
Is Sanofi an investor in T-Therapeutics?
Yes, through Sanofi Ventures, an existing backer of the company before its $133m Series B in November 2026.Source: BioPharm International
What is Sanofi Ventures?
The corporate venture capital Arm of the French drugmaker Sanofi.Source: Sanofi
Has Sanofi bought a British biotech?
Yes. Sanofi bought Kymab, a Cambridge antibody company, in 2021.Source: Lowdown
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.